Sign up
Pharma Capital

Living Cell Technologies shares rise on positive initial Parkinson’s disease study results

The company’s shares are trading about 10% higher intra-day, at 5.6 cents.
Parkinson's disease
Parkinson's disease is a progressive nervous system disorder that affects movement.

Living Cell Technologies Ltd (ASX:LCT) has revealed statistically significant improvements in patients who received NTCELL capsule implantation on the brain, in the phase IIb study of NTCELL for Parkinson’s disease.

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of pathogen-free pigs.

Following implantation into a damaged site within the brain, NTCELL functions as a neurochemical factory secreting multiple nerve growth factors that promote new central nervous system growth and repair disease-induced nerve degeneration.

The study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.

Efficacy was measured using the Unified Parkinson’s Disease Rating Scale (UPDRS).

Initial data from the 18-month follow up of 18 patients show a statistically significant improvement (p = <0.05) in the UPDRS in the patients who received 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery.

No benefit was observed when 120 NTCELL capsules were implanted, there being evidence of inflammation which may have compromised efficacy in this group.

Auckland City Hospital principal investigator Dr Barry Snow said: “The statistical improvement seen at 12 months has been sustained; variation between recipients is expected with the small number of subjects.

“The next step is further in-depth analysis to understand the data on all efficacy measurements both on and off normal symptomatic treatment.”

Register here to be notified of future LCT Company articles
View full LCT profile View Profile
View All

Related Articles

Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Woman touching face
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.